Abstract
Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) is a rare diffuse large B-cell lymphoma confined to the skin of the legs. The typical presentation is characterized by solitary or multiple growing plaques, usually confined to one leg. We report a case of PCDLBCL-LT of activated B-cell subtype characterized by multiple local relapses in the legs, initially, and systemic relapses about seven years after the diagnosis. Local relapses were sensitive to radiation therapy. Cutaneous and systemic relapses responded well to immunomodulatory therapy with lenalidomide followed by Bruton's tyrosine kinase inhibition with ibrutinib. Ibrutinib is the only treatment that resulted in long-lasting complete remission. Lenalidomide and especially ibrutinib appear to have a significant activity against this lymphoma and should be incorporated in the treatment of this resistant and aggressive lymphoma. To our knowledge, this is the first case of PCDLBCL-LT reported in the literature exhibiting a complete response to ibrutinib.
References
Oct 26, 2000·Journal of the American Academy of Dermatology·H S ZackheimM Kashani-Sabet
Sep 25, 2003·Blood·Christine P HansWing C Chan
Jun 11, 2005·Blood·Kazuo KodamaLorenzo Cerroni
Sep 19, 2007·Archives of Dermatology·Florent GrangeTony Petrella
Jun 24, 2008·Blood·Nancy J SenffUNKNOWN International Society for Cutaneous Lymphoma
Jul 9, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter H WiernikThomas M Habermann
Jan 14, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T E WitzigM S Czuczman
Apr 16, 2011·Cancer·Francisco J Hernandez-IlizaliturriMyron S Czuczman
Jun 29, 2011·British Journal of Haematology·Antonia Lopez-GironaRajesh Chopra
Nov 3, 2011·Proceedings·Vibha ThomasRobert Mennel
Jul 19, 2013·The Journal of Investigative Dermatology·Lianne KoensCornelis P Tensen
Aug 20, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Grzegorz S NowakowskiThomas E Witzig
Mar 26, 2015·Seminars in Hematology·Ryan M YoungLouis M Staudt
Jul 28, 2015·The Lancet Oncology·Vicki Brower
Citations
Dec 20, 2016·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Jan P Nicolay, Marion Wobser
Dec 20, 2016·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Jan P Nicolay, Marion Wobser
Jul 25, 2018·American Journal of Hematology·Ryan A Wilcox
Aug 3, 2017·Terapevticheskiĭ arkhiv·N G GabeevaV G Savchenko
Jan 15, 2020·Der Pathologe·Marion Wobser, Matthias Goebeler
Jun 12, 2020·Cancers·Maëlle DumontAdèle de Masson
Sep 13, 2019·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·Marion Wobser, Matthias Goebeler
Aug 21, 2020·American Journal of Hematology·Alexandra C HristovRyan A Wilcox
Sep 22, 2016·American Journal of Hematology·Ryan A Wilcox
Dec 5, 2019·Frontiers in Oncology·Giulia Tadiotto CicognaMauro Alaibac
Jun 23, 2020·Curēus·Ammar Al-ObaidiPhu Truong
Aug 14, 2019·Clinical Oncology : a Journal of the Royal College of Radiologists·L Specht, L Skov
Oct 1, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R WillemzeUNKNOWN ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org